Tag: preclinical
-
NIH Funds Heart Tissue Regeneration Tests in Pigs
An experimental drug to help grow new heart tissue after a heart attack is advancing to tests in pigs, with help from National Institutes of Health.
-
Wearable-Implant Diagnostics Device in Development
A university engineering lab is developing a device combining a sensor chip implanted under the skin and wrist band to diagnose serious diseases and transmit the data.
-
Engineered Insulin-Producing Cells to Be Grown in Lab
A team from three universities is developing in the lab synthetic islet cells, the cells that produce insulin in the pancreas, for eventual transplantation in people with type 1 diabetes.
-
Vaccines in Development for Opioid Combinations
Researchers studying the immune system as a weapon against opioid addiction say they can develop vaccines that block combinations of opioids, like those sold on the street.
-
3-D Printing Process Developed for Living Tissue
Researchers in the U.K. devised 3-D printing techniques for human and animal cells to produce functioning tissue with multiple types of cells.
-
Alliance to Develop Rare Cancer Preclinical Models
A coalition of a patient advocacy organization, research institute, and cancer research company are implanting mice with human tumors to help study a rare form of cancer.
-
Injectable Patch Designed to Repair Heart Tissue
An injectable soft mesh patch seeded with cardiac cells is shown to fix damaged heart tissue in tests with lab animals, as an alternative to open-heart surgery.
-
Gene-Edited Skin Grafts Shown to Control Glucose Levels
Skin grafts derived from genetically edited stem cells were shown in tests with lab mice to reduce glucose levels and weight gain that result from a high-fat diet.
-
University, Company Employ AI for Anti-Aging Drugs
The medical analytics company Insilico Medicine is partnering with a university in Denmark to apply artificial intelligence to find new treatments for diseases associated with early aging.
-
Gene Editing, Therapy Company Gains $83.5M in Venture Funds
A biotechnology company designing treatments with gene edits and transfers using benign viruses is raising $83.5 million in its second venture funding round.